These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1106 related articles for article (PubMed ID: 30796368)

  • 21. Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors.
    Heidrich I; Deitert B; Werner S; Pantel K
    Cancer Metastasis Rev; 2023 Mar; 42(1):161-182. PubMed ID: 36607507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA).
    Chin RI; Chen K; Usmani A; Chua C; Harris PK; Binkley MS; Azad TD; Dudley JC; Chaudhuri AA
    Mol Diagn Ther; 2019 Jun; 23(3):311-331. PubMed ID: 30941670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liquid biopsy in CNS tumors: Current status & future perspectives.
    Husain N; Husain A; Mishra S; Srivastava P
    Indian J Pathol Microbiol; 2022 May; 65(Supplement):S111-S121. PubMed ID: 35562141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Applications of Liquid Biopsy for Surgical Patients With Cancer: A Review.
    Mahuron KM; Fong Y
    JAMA Surg; 2024 Jan; 159(1):96-103. PubMed ID: 37910091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma.
    Calapre L; Warburton L; Millward M; Ziman M; Gray ES
    Cancer Lett; 2017 Sep; 404():62-69. PubMed ID: 28687355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA.
    Luo H; Wei W; Ye Z; Zheng J; Xu RH
    Trends Mol Med; 2021 May; 27(5):482-500. PubMed ID: 33500194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. cfDNA-Based NGS IG Analysis in Lymphoma.
    Pott C; Kotrova M; Darzentas N; Brüggemann M; Khouja M;
    Methods Mol Biol; 2022; 2453():101-117. PubMed ID: 35622323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current and future perspectives of liquid biopsies in genomics-driven oncology.
    Heitzer E; Haque IS; Roberts CES; Speicher MR
    Nat Rev Genet; 2019 Feb; 20(2):71-88. PubMed ID: 30410101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liquid Biopsy in Oral Cancer.
    Lousada-Fernandez F; Rapado-Gonzalez O; Lopez-Cedrun JL; Lopez-Lopez R; Muinelo-Romay L; Suarez-Cunqueiro MM
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liquid Biopsy: Current Status and Future Perspectives.
    Mader S; Pantel K
    Oncol Res Treat; 2017; 40(7-8):404-408. PubMed ID: 28693023
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minimal Residual Disease in Prostate Cancer.
    Cackowski FC; Taichman RS
    Adv Exp Med Biol; 2018; 1100():47-53. PubMed ID: 30411259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in the diagnosis and prognosis of minimal residual lesions of breast cancer.
    Cui S; Liu W; Wang W; Miao K; Guan X
    Pathol Res Pract; 2023 May; 245():154428. PubMed ID: 37028109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toward liquid biopsies in cancer treatment: application of circulating tumor DNA.
    Barlebo Ahlborn L; Østrup O
    APMIS; 2019 May; 127(5):329-336. PubMed ID: 30784124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circulating tumour cells in breast cancer--review.
    Vertakova KB; Sanislo L; Spanik S; Svec J; Ondrus D
    Klin Onkol; 2010; 23(2):86-91. PubMed ID: 20465086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating tumour cells and DNA as liquid biopsies in gastrointestinal cancer.
    Nordgård O; Tjensvoll K; Gilje B; Søreide K
    Br J Surg; 2018 Jan; 105(2):e110-e120. PubMed ID: 29341153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ctDNA as promising tool for the assessment of minimal residual disease (MRD) and the need of an adjuvant treatment in gastroesophageal adenocarcinoma.
    Piva VM; De Grandis MC; Zuin IS; Angerilli V; Nappo F; Alfieri R; Ahcene Djaballah S; Murgioni S; Bergamo F; Fassan M; Valmasoni M; Lonardi S
    Updates Surg; 2023 Feb; 75(2):305-312. PubMed ID: 36272058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Commercial ctDNA Assays for Minimal Residual Disease Detection of Solid Tumors.
    Chen K; Shields MD; Chauhan PS; Ramirez RJ; Harris PK; Reimers MA; Zevallos JP; Davis AA; Pellini B; Chaudhuri AA
    Mol Diagn Ther; 2021 Nov; 25(6):757-774. PubMed ID: 34725800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Promises and Pitfalls of Using Liquid Biopsy for Precision Medicine.
    Rossi G; Ignatiadis M
    Cancer Res; 2019 Jun; 79(11):2798-2804. PubMed ID: 31109952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methods for the Detection of Circulating Biomarkers in Cancer Patients.
    Mondelo-Macía P; Rodríguez-Ces AM; Suárez-Cunqueiro MM; Romay LM
    Adv Exp Med Biol; 2022; 1379():525-552. PubMed ID: 35761006
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liquid Biopsy in Endometrial Cancer: New Opportunities for Personalized Oncology.
    Muinelo-Romay L; Casas-Arozamena C; Abal M
    Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30087246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.